If you have been reading about CJC-1295 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-19. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
The Confederate commander in East Tennessee, Felix Zollicoffer, initially took a lenient stance toward the region's Unionists. In November 1861, however, Union guerrillas destroyed several railroad bridges across East Tennessee, prompting Confederate authorities to institute martial law. Suspected bridge-burning conspirators were tried and executed, and hundreds of other Unionists were jailed, causing the county jail at the southwestern corner of Main and Walnut streets to become overcrowded with prisoners. Brownlow was among those arrested, but was released after a few weeks. He spent 1862 touring the north in an attempt to rally support for a Union invasion of East Tennessee. Zollicoffer was replaced by John Crittenden in November 1861, and Crittenden was in turn replaced by Edmund Kirby Smith in March 1862, as Confederate authorities consistently struggled to find an acceptable commander for its East Tennessee forces. In June 1862, George Wilson, one of Andrews' Raiders, was tried and convicted in Knoxville. In July 1862, 40 Union soldiers captured by Nathan Bedford Forrest near Murfreesboro were marched down Gay Street, with Confederate soldiers jokingly reading aloud their personal correspondence afterward. The divided 2nd District sent representatives to both the U.S. Congress (Horace Maynard) and the Confederate Congress (William G. Swan) in 1861. Maynard, along with fellow East Tennessee Unionist Andrew Johnson, consistently pleaded with President Lincoln to send troops into the region.
The European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) (formerly EFCC) is a federation of national member societies of clinical chemistry and laboratory medicine from Europe. EFLM has its registered office in Brussels and its administrative office in Milan. EFLM is the European Regional member of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Temporary halogenation with bromine to a trans‑1,2‑dibromoalkane: the regeneration of the alkene then follows with preservation of conformation via elemental zinc or with titanocene dichloride. Protection through a Diels-Alder reaction: the transformation of an alkene with a diene leads to a cyclic alkene, which is nevertheless similarly endangered by electrophilic attack as the original alkene. The cleavage of a protecting diene proceeds thermically, for the Diels-Alder reaction is a reversible (equilibrium) reaction.
Sources: en.wikipedia.org
Rutherfordium is a synthetic chemical element; it has symbol Rf and atomic number 104. It is named after physicist Ernest Rutherford. As a synthetic element, it is not found in nature and can only be made in a particle accelerator. It is radioactive; the most stable known isotope, 267Rf, has a half-life of about 48 minutes. In the periodic table, it is a d-block element and the second of the fourth-row transition elements. It is in period 7 and is a group 4 element. Chemistry experiments have confirmed that rutherfordium behaves as the heavier homolog to hafnium in group 4. The chemical properties of rutherfordium are known only partly. They compare well with the other group 4 elements, though some calculations had indicated that the element might show significantly different properties due to relativistic effects. In the 1960s, small amounts of rutherfordium were produced at Joint Institute for Nuclear Research (JINR) in the Soviet Union and at Lawrence Berkeley National Laboratory in California. Priority of discovery and hence the name of the element was disputed between Soviet and American scientists, and it was not until 1997 that the International Union of Pure and Applied Chemistry (IUPAC) established rutherfordium as the official name of the element.
An Iranian ballistic missile strike damaged an Israeli drone factory in Petah Tikva. On the same day, Iran's army chief, Amir Hatami, stated that if US forces invade the country, "not a single person" among the invaders will survive.
==== Proboscidean research ==== A study on the morphology of the astragalus and calcaneus in extant and extinct proboscideans, providing evidence of morphological changes of ankles bones related to increase of the body mass and evolution of the columnar posture of members of the group, is published by Tetaert et al. (2026). A study on humeri of extant and extinct proboscideans, providing evidence of different impact of compressive loading on humeri representing slender and robust morphotypes, is published by Wagner, Chatar & Hennekam (2026). Semprebon, Sanders & Uttecht (2026) reconstruct diets and habitats of Moeritherium and Phiomia on the basis of their tooth wear, interpreting the former taxon as feeding on soft vegetation and likely frequenting aquatic habitats, and interpreting the latter taxon as likely living in a terrestrial forest or woodland environment. Alquézar-Blesa et al. (2026) study the feeding behaviors of Miocene Gomphotherium and Prodeinotherium from Artesilla and Tarazona (Spain), reporting evidence from the study of tooth wear indicative of a greater degree of dietary flexibility than indicated by tooth morphology, including evidence of grass consumption. Bader, Gasparik & Segesdi (2026) compare the microanatomy of femur of Deinotherium giganteum and mammoths, reporting evidence of differences that might be linked to distinct weight-bearing adaptations. Description of new fossil material of Mammut shansiense from the Yushe Basin (China) and a study on the phylogenetic affinities of the species is published by Zhang et al.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.